Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 13 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 3 Nov 2018.
- 13 Feb 2017 Status changed from not yet recruiting to recruiting.
- 22 Mar 2016 New trial record